Floatz logo

Therapeutic Asset Ratings

6,299 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Trop2-Car-Nk
Adenocarcinoma
M.D. Anderson Cancer CenterP1/2CC (45)
tsn1611
Cancer
Tyligand Pharmaceuticals (Suzhou) LimitedP1/2CC (45)
Tub-030
Colorectal Cancer
Tubulis GmbHP1/2CC (45)
Tub-030
Head And Neck Squamous Cell Carcinoma
Tubulis GmbHP1/2CC (45)
Tub-030
Small Cell Lung Carcinoma
Tubulis GmbHP1/2CC (45)
Tuvonralimab
Primary Peritoneal Carcinoma
Shanghai Gynecologic Oncology GroupP1/2CC (45)
ucb4594
Pancreatic Neoplasm
Cancer Research UKP1/2CC (45)
ucb4594
Head And Neck Squamous Cell Carcinoma
Cancer Research UKP1/2CC (45)
ucb4594
Uterine Cervix Neoplasm
Cancer Research UKP1/2CC (45)
Umbilical Cord Mesenchymal Stem Cell
Diabetes Mellitus
Nguyen Ton Ngoc HuynhP1/2CC (45)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells
Breast Cancer
Margaret Gatti-MaysP1/2CC (45)
Valproic Acid
Hemophilia
Xue-chun LuP1/2CC (45)
Vebeglogene Autotemcel
Beta Thalassemia
Lantu BiopharmaP1/2CC (45)
Veliparib
Minimally Invasive Lung Adenocarcinoma
National Cancer Institute (NCI)P1/2CC (45)
Verbrinacogene Setparvovec
Hemophilia B
Spur TherapeuticsP1/2CC (45)
Vibostolimab
Renal Cell Carcinoma
Merck Sharp & Dohme LLCP1/2CC (45)
Vio-01
Ovarian Cancer
Valerio TherapeuticsP1/2CC (45)
Vmd-102
Uveal Melanoma
VM Discovery, Inc.P1/2CC (45)
Vmd-102
Renal Cell Carcinoma
VM Discovery, Inc.P1/2CC (45)
Vnx-101
Burkitt Lymphoma
Vironexis Biotherapeutics Inc.P1/2CC (45)
Vnx-101
Non-Hodgkin Lymphoma
Vironexis Biotherapeutics Inc.P1/2CC (45)
Vnx-101
Primary Mediastinal Large B-Cell Lymphoma
Vironexis Biotherapeutics Inc.P1/2CC (45)
vo659
Huntington Disease
Vico Therapeutics B. V.P1/2CC (45)
Vorinostat
Lung Cancer
H. Lee Moffitt Cancer Center and Research InstituteP1/2CC (45)
Vsv
Cancer
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP1/2CC (45)
Showing 3901 to 3925 of 6,299 assets
PreviousPage 157 of 252Next